OPR - Delayed Quote • USD AKRO Jan 2025 2.500 call (AKRO250117C00002500) Follow 29.01 0.00 (0.00%) At close: March 8 at 11:10 AM EST Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for AKRO250117C00002500 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: AKRO Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks Ozempic Can’t Do It All—A Potential New Blockbuster Is a Reminder of That Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology President and CEO Andrew Cheng Sells 75,000 Shares of Akero Therapeutics Inc (AKRO) Akero Therapeutics Announces Pricing of Public Offering of Common Stock Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study Akero Therapeutics Announces Proposed Public Offering of Common Stock Why Akero Rocketed — And Pulled Rival 89bio Higher — On Results In Liver Disease Treatment Data Suggests Makers of Fatty Liver Treatments Won’t Be Displaced by Obesity Drugs
